Cargando…

Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India

INTRODUCTION: Several sociodemographic variables, including ethnic inequality, have been identified as potentially influencing the uptake of COVID-19 vaccinations. To develop herd immunity against COVID-19, at least 70–85% of the population must be vaccinated. As the situation with COVID-19 changes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvaraj, Preethi, Muthu, Sathish, Jeyaraman, Naveen, Prajwal, Gollahalli Shivashankar, Jeyaraman, Madhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. on behalf of INDIACLEN. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824716/
https://www.ncbi.nlm.nih.gov/pubmed/35155844
http://dx.doi.org/10.1016/j.cegh.2022.100983
_version_ 1784647060798046208
author Selvaraj, Preethi
Muthu, Sathish
Jeyaraman, Naveen
Prajwal, Gollahalli Shivashankar
Jeyaraman, Madhan
author_facet Selvaraj, Preethi
Muthu, Sathish
Jeyaraman, Naveen
Prajwal, Gollahalli Shivashankar
Jeyaraman, Madhan
author_sort Selvaraj, Preethi
collection PubMed
description INTRODUCTION: Several sociodemographic variables, including ethnic inequality, have been identified as potentially influencing the uptake of COVID-19 vaccinations. To develop herd immunity against COVID-19, at least 70–85% of the population must be vaccinated. As the situation with COVID-19 changes, the public's perception keeps fluctuating. We designed a survey to determine the prevalence of vaccinated individuals and the rate of infectivity post-vaccination. We also aimed to study the clinical manifestations and infectivity of the SARS-CoV-2 virus post-vaccination. MATERIALS AND METHODS: A cross-sectional study was conducted from May 10, 2021 to July 10, 2021 across India through a pre-tested validated semi-structured self-administered electronic questionnaire, to the study subjects with objectives explained and the confidentiality of the data and results had been assured. The questionnaires were prepared using Google forms and the link was sent across social media platforms such as WhatsApp, Facebook, and various social platforms where people are actively engaged following the restrictions and protocols of social distancing. General demographic data, followed by their lifestyle and comorbid conditions, and data on their vaccination, infectivity, and side effects were collected. RESULTS: We included 2334 participants in the study, of which the majority of the study participants were in the age group of 25–34 years (38.6%). 1729 were vaccinated individuals of which 80.7% had received Covishield and 17.8% had received Covaxin. Around 61.1% have received both doses among 1729 vaccinated individuals and 38.9% had received only one dose of vaccine. The majority of the fully vaccinated individuals had a gap of 4–5 weeks for the second dose (37.1%) followed by 5–6 weeks (11.2%). Post-vaccination 50.8% had experienced muscle pain, 46% had experienced fatigue, 36.5% weakness, and 12.3% back pain. Among vaccinated 26% turned out to be COVID-19 positive and 44.5% non-vaccinated got infected. The odds of infection among non -vaccinated individuals was 2.27 times higher than vaccinated individuals. Individuals who encountered the viral antigen for the second time experienced either through vaccination or infection demonstrated exaggerated inflammatory response which is explained by the antibody-dependent enhancement phenomenon without life-threatening complications. CONCLUSION: Although more than 50% of the vaccinated individuals experienced some form of musculoskeletal side effects, we noted a high acceptance rate (74%) of vaccination among the participants. The vaccinated individuals were two times safer from infection compared to the non-vaccinated individuals.
format Online
Article
Text
id pubmed-8824716
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier B.V. on behalf of INDIACLEN.
record_format MEDLINE/PubMed
spelling pubmed-88247162022-02-09 Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India Selvaraj, Preethi Muthu, Sathish Jeyaraman, Naveen Prajwal, Gollahalli Shivashankar Jeyaraman, Madhan Clin Epidemiol Glob Health Article INTRODUCTION: Several sociodemographic variables, including ethnic inequality, have been identified as potentially influencing the uptake of COVID-19 vaccinations. To develop herd immunity against COVID-19, at least 70–85% of the population must be vaccinated. As the situation with COVID-19 changes, the public's perception keeps fluctuating. We designed a survey to determine the prevalence of vaccinated individuals and the rate of infectivity post-vaccination. We also aimed to study the clinical manifestations and infectivity of the SARS-CoV-2 virus post-vaccination. MATERIALS AND METHODS: A cross-sectional study was conducted from May 10, 2021 to July 10, 2021 across India through a pre-tested validated semi-structured self-administered electronic questionnaire, to the study subjects with objectives explained and the confidentiality of the data and results had been assured. The questionnaires were prepared using Google forms and the link was sent across social media platforms such as WhatsApp, Facebook, and various social platforms where people are actively engaged following the restrictions and protocols of social distancing. General demographic data, followed by their lifestyle and comorbid conditions, and data on their vaccination, infectivity, and side effects were collected. RESULTS: We included 2334 participants in the study, of which the majority of the study participants were in the age group of 25–34 years (38.6%). 1729 were vaccinated individuals of which 80.7% had received Covishield and 17.8% had received Covaxin. Around 61.1% have received both doses among 1729 vaccinated individuals and 38.9% had received only one dose of vaccine. The majority of the fully vaccinated individuals had a gap of 4–5 weeks for the second dose (37.1%) followed by 5–6 weeks (11.2%). Post-vaccination 50.8% had experienced muscle pain, 46% had experienced fatigue, 36.5% weakness, and 12.3% back pain. Among vaccinated 26% turned out to be COVID-19 positive and 44.5% non-vaccinated got infected. The odds of infection among non -vaccinated individuals was 2.27 times higher than vaccinated individuals. Individuals who encountered the viral antigen for the second time experienced either through vaccination or infection demonstrated exaggerated inflammatory response which is explained by the antibody-dependent enhancement phenomenon without life-threatening complications. CONCLUSION: Although more than 50% of the vaccinated individuals experienced some form of musculoskeletal side effects, we noted a high acceptance rate (74%) of vaccination among the participants. The vaccinated individuals were two times safer from infection compared to the non-vaccinated individuals. The Authors. Published by Elsevier B.V. on behalf of INDIACLEN. 2022 2022-02-09 /pmc/articles/PMC8824716/ /pubmed/35155844 http://dx.doi.org/10.1016/j.cegh.2022.100983 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Selvaraj, Preethi
Muthu, Sathish
Jeyaraman, Naveen
Prajwal, Gollahalli Shivashankar
Jeyaraman, Madhan
Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India
title Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India
title_full Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India
title_fullStr Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India
title_full_unstemmed Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India
title_short Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India
title_sort incidence and severity of sars-cov-2 virus post covid-19 vaccination: a cross-sectional study in india
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824716/
https://www.ncbi.nlm.nih.gov/pubmed/35155844
http://dx.doi.org/10.1016/j.cegh.2022.100983
work_keys_str_mv AT selvarajpreethi incidenceandseverityofsarscov2viruspostcovid19vaccinationacrosssectionalstudyinindia
AT muthusathish incidenceandseverityofsarscov2viruspostcovid19vaccinationacrosssectionalstudyinindia
AT jeyaramannaveen incidenceandseverityofsarscov2viruspostcovid19vaccinationacrosssectionalstudyinindia
AT prajwalgollahallishivashankar incidenceandseverityofsarscov2viruspostcovid19vaccinationacrosssectionalstudyinindia
AT jeyaramanmadhan incidenceandseverityofsarscov2viruspostcovid19vaccinationacrosssectionalstudyinindia